<DOC>
	<DOCNO>NCT02052609</DOCNO>
	<brief_summary>This study design evaluate safety efficacy long-term exposure KHK4827 subject plaque psoriasis ( psoriasis vulgaris , psoriatic erythroderma ) complete Study 4827-003 ( Study 003 ) subject pustular psoriasis ( generalize ) psoriatic erythroderma complete Study 4827-004 ( Study 004 ) .</brief_summary>
	<brief_title>A Phase 3 Clinical Study KHK 4827</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Dermatitis , Exfoliative</mesh_term>
	<criteria>Subject voluntarily sign write informed consent form participate study Subject complete week 52 evaluation either Study 003 004 Subject serious infection , define require systemic treatment antibiotic antiviral ( exclude oral administration ) Subject judge ineligible participation study investigators/sub investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>